70 related articles for article (PubMed ID: 37183966)
1. Ultrasensitive NGS MRD assessment in Ph+ ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1.
Short NJ; Jabbour E; Macaron W; Ravandi F; Jain N; Kanagal-Shamanna R; Patel KP; Loghavi S; Haddad FG; Yilmaz M; Issa GC; Kebriaei P; Kornblau SM; Pelletier S; Flores W; Matthews J; Garris R; Kantarjian H
Am J Hematol; 2023 Aug; 98(8):1196-1203. PubMed ID: 37183966
[TBL] [Abstract][Full Text] [Related]
2. SOHO State of the Art Updates and Next Questions: Update on the Approach to Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
Haddad FG; Jabbour E; Short NJ; Jain N; Kantarjian H
Clin Lymphoma Myeloma Leuk; 2024 May; 24(5):271-276. PubMed ID: 38185587
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of next-generation sequencing for measurable residual disease monitoring in three major fusion transcript subtypes of B-precursor acute lymphoblastic leukaemia.
Huang YJ; Chen SH; Liu HC; Jaing TH; Yeh TC; Kuo MC; Lin TL; Chen CC; Wang SC; Chang TK; Hsiao CC; Liang DC; Shih LY
Pathology; 2024 Apr; ():. PubMed ID: 38719770
[TBL] [Abstract][Full Text] [Related]
4. SOHO State of the Art Updates and Next Questions, Measurable Residual Disease in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
Short NJ; Jabbour E; Kantarjian H
Clin Lymphoma Myeloma Leuk; 2024 Feb; ():. PubMed ID: 38485650
[TBL] [Abstract][Full Text] [Related]
5. Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA.
Sánchez R; Dorado S; Ruíz-Heredia Y; Martín-Muñoz A; Rosa-Rosa JM; Ribera J; García O; Jimenez-Ubieto A; Carreño-Tarragona G; Linares M; Rufián L; Juárez A; Carrillo J; Espino MJ; Cáceres M; Expósito S; Cuevas B; Vanegas R; Casado LF; Torrent A; Zamora L; Mercadal S; Coll R; Cervera M; Morgades M; Hernández-Rivas JÁ; Bravo P; Serí C; Anguita E; Barragán E; Sargas C; Ferrer-Marín F; Sánchez-Calero J; Sevilla J; Ruíz E; Villalón L; Del Mar Herráez M; Riaza R; Magro E; Steegman JL; Wang C; de Toledo P; García-Gutiérrez V; Ayala R; Ribera JM; Barrio S; Martínez-López J
Sci Rep; 2022 Jul; 12(1):13057. PubMed ID: 35906470
[TBL] [Abstract][Full Text] [Related]
6. A surrogate molecular approach for the detection of Philadelphia chromosome-like B-acute lymphoblastic leukemia.
Gupta DG; Varma N; Abdulkadir SA; Sreedharanunni S; Sachdeva MUS; Naseem S; Bose P; Binota J; Malhotra P; Khadwal A; Trehan A; Varma S
Cancer; 2024 Mar; 130(5):713-726. PubMed ID: 37819686
[TBL] [Abstract][Full Text] [Related]
7. Digital droplet PCR for T315I BCR::ABL1 KD mutation assessment in adult Ph-positive acute lymphoblastic leukemia with a minimal residual disease increase.
Cardinali D; Beldinanzi M; Ansuinelli M; Elia L; Della Starza I; Bellomarino V; Matarazzo M; Di Trani M; Cola M; Salutari P; Cedrone M; Bassan R; De Gobbi M; Della Porta MG; De Simone M; Alati C; Fracchiolla NS; Lunghi M; Intermesoli T; Cardinali V; Mulè A; Guarini A; Foà R; Chiaretti S
Leuk Lymphoma; 2023; 64(11):1884-1887. PubMed ID: 37452789
[No Abstract] [Full Text] [Related]
8. Comparison of Measurable Residual Disease in Pediatric B-Lymphoblastic Leukemia Using Multiparametric Flow Cytometry and Next-Generation Sequencing.
Hwang SM; Oh I; Kwon SR; Lee JS; Seong MW
Ann Lab Med; 2024 Jul; 44(4):354-358. PubMed ID: 38237930
[TBL] [Abstract][Full Text] [Related]
9. Concordance of Next-Generation Sequencing and Multiparametric Flow Cytometry Methods for Detecting Measurable Residual Disease in Adult Acute Lymphoblastic Leukemia: Optimizing Prediction of Clinical Outcomes From a Single-Center Study.
Ashouri K; Nittur V; Ginosyan AA; Hwang J; Adnani B; Chen D; Savitala-Damerla L; Schiff K; Chaudhary P; Kovach AE; Ladha A; Siddiqi I; Ali A; Woan K; Tam E; Yaghmour G
Clin Lymphoma Myeloma Leuk; 2024 Mar; 24(3):e59-e66.e2. PubMed ID: 38061959
[TBL] [Abstract][Full Text] [Related]
10. Clinical impact of minimal residual disease and genetic subtypes on the prognosis of childhood acute lymphoblastic leukemia.
Yu CH; Jou ST; Su YH; Coustan-Smith E; Wu G; Cheng CN; Lu MY; Lin KH; Wu KH; Chen SH; Huang FL; Chang HH; Wang JL; Yen HJ; Li MJ; Chou SW; Ho WL; Liu YL; Chang CC; Lin ZS; Lin CY; Chen HY; Ni YL; Lin DT; Lin SW; Yang JJ; Ni YH; Pui CH; Yu SL; Yang YL
Cancer; 2023 Mar; 129(5):790-802. PubMed ID: 36537587
[TBL] [Abstract][Full Text] [Related]
11. Next-generation sequencing-based MRD in adults with ALL undergoing hematopoietic cell transplantation.
Liang EC; Dekker SE; Sabile JMG; Torelli S; Zhang A; Miller K; Shiraz P; Hayes-Lattin B; Leonard JT; Muffly L
Blood Adv; 2023 Jul; 7(14):3395-3402. PubMed ID: 37196642
[TBL] [Abstract][Full Text] [Related]
12. Analytical Performance Evaluation of a Digital Real-Time PCR for Quantifying Major BCR::ABL1 Transcripts.
Lee SJ; Lee JM; Ahn A; Lee SE; Hong Y; Lee GD; Song HW; Song MS; Shin SS; Kim M; Kim Y
J Clin Lab Anal; 2024 Apr; 38(7):e25034. PubMed ID: 38525919
[TBL] [Abstract][Full Text] [Related]
13. 'Evaluation of adverse prognostic gene alterations & MRD positivity in BCR::ABL1-like B-lineage acute lymphoblastic leukaemia patients, in a resource-constrained setting.
Gupta DG; Varma N; Sreedharanunni S; Abdulkadir SA; Naseem S; Sachdeva MUS; Binota J; Bose P; Malhotra P; Khadwal A; Varma S
Br J Cancer; 2023 Jul; 129(1):143-152. PubMed ID: 37156894
[TBL] [Abstract][Full Text] [Related]
14. The Outcome of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Experience from a Referral Center in South India.
Antonisamy N; Boddu D; John R; Korrapolu RSA; Balasubramanian P; Arunachalam AK; Joseph LL; Srinivasan HN; Mathew LG; Totadri S
Indian J Hematol Blood Transfus; 2024 Jan; 40(1):61-67. PubMed ID: 38312177
[TBL] [Abstract][Full Text] [Related]
15. Hematological, clinical, immunophenotypic characterization, and treatment outcomes of prognostically significant genetic subtypes of B-lineage acute lymphoblastic leukemia: A report of 1021 patients from India.
Gupta DG; Varma N; Sharma P; Truica MI; Abdulkadir SA; Singh P; Singh Sachdeva MU; Naseem S; Siddiqui MR; Bose P; Binota J; Malhotra P; Khadwal A; Trehan A; Varma S
Cancer; 2023 Nov; 129(21):3390-3404. PubMed ID: 37498973
[TBL] [Abstract][Full Text] [Related]
16. Quantification of Measurable Residual Disease Detection by Next-Generation Sequencing-Based Clonality Testing in B-Cell and Plasma Cell Neoplasms.
Liu Y; Ho C; Yu W; Huang Y; Miller J; Gao Q; Syed M; Ma Y; Wang M; Maciag L; Petrova-Drus K; Zhu M; Yao J; Vanderbilt C; Durham B; Benhamida J; Ewalt MD; Dogan A; Roshal M; Nafa K; Arcila ME
J Mol Diagn; 2024 Mar; 26(3):168-178. PubMed ID: 38103591
[TBL] [Abstract][Full Text] [Related]
17. Utility of Measurable Residual Disease (MRD) Assessment in Mantle Cell Lymphoma.
Wu S; Blombery P; Westerman D; Tam CS
Curr Treat Options Oncol; 2023 Aug; 24(8):929-947. PubMed ID: 37249800
[TBL] [Abstract][Full Text] [Related]
18. Reverse Transcription Can Critically Impact the Diagnostic Outcome of
Spiess B; Kleiner H; Tarnopolscaia I; Naumann N; Fabarius A; Hofmann WK; Saussele S; Seifarth W
Cancers (Basel); 2023 Aug; 15(15):. PubMed ID: 37568730
[TBL] [Abstract][Full Text] [Related]
19. Updates on lymphoblastic leukemia/lymphoma classification and minimal/measurable residual disease analysis.
Kovach AE; Wood BL
Semin Diagn Pathol; 2023 Nov; 40(6):457-471. PubMed ID: 37953192
[TBL] [Abstract][Full Text] [Related]
20. Application of droplet digital PCR in minimal residual disease monitoring of rare fusion transcripts and mutations in haematological malignancies.
Ip BBK; Wong ATC; Law JHY; Au CH; Ma SY; Chim JCS; Liang RHS; Leung AYH; Wan TSK; Ma ESK
Sci Rep; 2024 Mar; 14(1):6400. PubMed ID: 38493200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
